BRISBANE, Australia,
May 24, 2018 /PRNewswire/
-- Q-Pharm, a leading Australian early-phase clinical research
organization announced today that in collaboration with the Trade
Investment Queensland (TIQ) Japan
office, it conducted a high-level seminar in Tokyo, Japan. The seminar held on
17th May, 2018 was facilitated by Japan Bioindustry
Association, and attracted strong attendance from major Japanese
pharmaceutical, biotechnology, and clinical research organisations,
as well as Japanese government representatives.
Q-Pharm provided the audience with an in-depth understanding of
the benefits of conducting early-phase clinical trials at their
state-of-the-art facilities in Queensland, Australia. Information was also
provided on incentives available through the Queensland and Australian governments for
companies interested in conducting clinical trials at Q-Pharm. One
such incentive program from the Queensland state government can provide up to
50 percent of eligible fees to a cap of $250,000 per project, while the Australian
Research & Development Tax Incentive Scheme for eligible
companies can provide up to an additional 43.5% tax refund. These
programs, along with Q-Pharm's proven capabilities and
international reputation in the industry, provide significant
incentives for Australian and international companies to conduct
their early-phase clinical trials at Q-Pharm.
During his presentation, Craig
Hurren, Chief Commercial Officer for Q-Pharm said, "Q-Pharm
has a very impressive history of conducting early-phase clinical
trials to globally accepted standards of safety and quality.
Q-Pharm's excellent infrastructure and highly experienced people
can maximize efficiency and outcome for Japanese drug and medical
device development companies wanting to conduct early-phase
clinical trials."
Queensland Trade and Investment Commissioner in Japan, Mr. Tak
Adachi, mentioned that it was perfect timing for Japanese
pharmaceutical and biotechnology companies to focus on the
excellent opportunities Q-Pharm provides in the area of early
clinical development. Dr. Tufail
Syed, CEO of Q-Pharm stated, "Q-Pharm has developed strong
capabilities in the areas of study design, commercialization
strategy, medical writing, and recruitment of study participants,
as well as actual study conduct. We look forward to developing
long-term partnerships with Japanese companies through our
considerable expertise and
experience."
ABOUT Q-PHARM
Q-Pharm is a state-of-the-art early-phase clinical trials
company providing a broad range of high-quality services for
commercial and academic clients from around the world. Since 2002,
Q-Pharm has safely and successfully conducted more than 400
early-phase clinical trials in a wide variety of therapeutic areas.
Q-Pharm's highly qualified teams and leaders have a wealth of
experience in clinical development, enabling Q-Pharm to understand
the needs of a diverse range of clients, and to meet and exceed
their expectations. Clinical trials conducted at Q-Pharm are
accepted by regulators throughout the world, including Australia, Europe, Asia,
and the Americas. Q-Pharm's speciality clinical trial
services include: Comparative PK/PD, SAD/MAD/Food Effect
studies, complex First-In-Human studies, vaccines studies, disease
challenge models, clinical development strategy and study design
consultation.
More information on Q-Pharm can be found on its website at
www.qpharm.com.au
Media Contact:
Thor Berg
Phone: +61 7 3845 3632
Email: marketing@qpharm.com.au
View original
content:http://www.prnewswire.com/news-releases/leading-australian-clinical-trials-company-q-pharm-organizes-seminar-in-tokyo-japan-300654846.html
SOURCE Q-Pharm